2nd International Conference on Tumor & Cancer Immunology and Immunotherapy
July 17 - 19, 2017 - Chicago NV USConference Series LLC
tumorimmunology@conferenceseries.com
Phone:6502689744
With the enormous response from the previous annual Tumor & Cancer Immunology conference 2016, Conference Series LLC invites all the participants from all over the world to attend 2nd International Conference on Tumor & Cancer Immunology-2017” during July 17-19, 2017 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology. Tumor Immunotherapy Market Value Report Highlights:- This report provides the market analysis for various technologies and applications used for the enrichment and detection of circulating tumor cells (CTCs). Based on tumor cell detection technologies, the market is segmented into molecular methods and optical methods. Furthermore, based on the applications, the CTC prognostic technologies market is segmented into breast cancer, colorectal cancer, prostate cancer and others (lung, ovarian and pancreatic cancer). Market forecast for all these segments has been provided in the report for the period 2012 to 2020 in terms of USD million, along with CAGR for the forecast period 2014 to 2020, considering 2013 as the base year. Cancer Immunotherapy Market Value Report Highlights The world spent an all-time high of $100 billion on cancer medicines in 2014, up 33 percent from $75 billion just five years ago. Overall, global spending on cancer drugs has risen at an annual rate of 6.5 percent for the past five years, but jumped 10.3 percent in 2014, a new report by the IMS Institute for Healthcare Informatics states. The spending is concentrated in only a handful of nations. The U.S. and the five largest European countries -- Britain, France, Germany, Italy and Spain -- make up two-thirds of global spending on these medicines. The U.S. spent $42.5 billion on cancer drugs in 2014, which accounted for 11.3 percent of the nation’s total spending on all drugs. The "pharmerging" group of countries (see graph below) represents 17 nations that IMS has identified as likely to represent 50 percent of global growth in pharmaceutical sales over a five-year period through 2017.